Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 9 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Health Research Inc. maintains a prosecution presence in the Biotechnology & Pharmaceuticals technology area with 10 pending office actions. These actions are handled by 10 distinct examiners, meaning that each pending case is under the review of a different USPTO official. The portfolio is further diversified across 8 distinct art units, highlighting the technical scope of the company's biological and pharmaceutical research and development efforts.
PHILIP R WIEST is identified as the busiest examiner, though he only manages 1 busiest examiner pending action. With 10 pending office actions distributed among 10 distinct examiners, the portfolio lacks any concentration of workload under 1 individual. The involvement of 8 distinct art units suggests that the company's patent filings are spread across many specialized sub-fields of biotechnology. This prosecution environment requires Health Research Inc. to manage multiple examiner relationships and adhere to the specific requirements of various art units simultaneously.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (9%) |
| §103 only | 3 (27%) |
| §112 only | 1 (9%) |
| Double-patenting only | 1 (9%) |
| Double-patenting + other | 1 (9%) |
| Multi-statute (no §101) | 4 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WIEST, PHILIP R | 1 | 81.3% | +16.3% |
| GRASER, JENNIFER E | 1 | 76.7% | +23.4% |
| JONES-FOSTER, ERICA NICOLE | 1 | 48.1% | +44.7% |
| PAGUIO FRISING, MICHELLE F | 1 | 71.1% | +39.3% |
| REDDIG, PETER J | 1 | 57.9% | +40.2% |
| PETERS, ALEC JON | 1 | 66.7% | +54.5% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
| HELLMAN, KRISTINA M | 1 | 65.3% | +55.3% |
| MULLINS, JESSICA LYNN | 1 | 49.5% | +34.0% |
| HUDSON, AMY ROSE | 1 | 74.9% | +11.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19102821 | LOCK TO POLE BIOMETRIC ACCESS INTRAVENEOUS MEDICATION LOCKBOX | WIEST, PHILIP R | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253384 | COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH | RZECZYCKI, PHILLIP MATTHEW | 60d overdue |
| 18439315 | METHOD FOR PROPHYLAXIS AND/OR TREATMENT OF ErbB2 POSITIVE CANCERS | REDDIG, PETER J | — |
| 18249816 | SYNERGISTIC INDUCTION OF IMMUNITY AGAINST RNA VIRUSES | HELLMAN, KRISTINA M | — |
| 18162995 | METHOD AND SYSTEM FOR CONCURRENT PHOTOTHERMAL ABLATION AND INTERSTITIAL PHOTODYNAMIC THERAPY | MULLINS, JESSICA LYNN | — |
| 17638518 | REACTIVATING P53 MUTANTS FOR CANCER TREATMENT BY TARGETING PROLIDASE (PEPD) | HUDSON, AMY ROSE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253384 | COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH | RZECZYCKI, PHILLIP MATTHEW | 60d overdue |
| 19102821 | LOCK TO POLE BIOMETRIC ACCESS INTRAVENEOUS MEDICATION LOCKBOX | WIEST, PHILIP R | — |
| 18830683 | COMPOSITION AND METHOD FOR GENERATING IMMUNITY TO BORRELIA BURGDORFERI | GRASER, JENNIFER E | — |
| 18708140 | DEPLETING EGFR AND HER2 OVERCOMES RESISTANCE TO EGFR INHIBITORS IN COLORECTAL CANCER | JONES-FOSTER, ERICA NICOLE | — |
| 18691035 | METHOD OF MITIGATION OF INJURIES CAUSED BY SYSTEMIC GENOTOXIC STRESS | PAGUIO FRISING, MICHELLE F | — |
| 18439315 | METHOD FOR PROPHYLAXIS AND/OR TREATMENT OF ErbB2 POSITIVE CANCERS | REDDIG, PETER J | — |
| 18259763 | ANTI-SURVIVIN ANTIBODIES FOR TREATMENT OF AUTOIMMUNE DISEASES | PETERS, ALEC JON | — |
| 18249816 | SYNERGISTIC INDUCTION OF IMMUNITY AGAINST RNA VIRUSES | HELLMAN, KRISTINA M | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| 1651 | 1 |
| 1642 | 1 |
| 1641 | 1 |
| 1625 | 1 |
| 1654 | 1 |
| 3792 | 1 |
| 1636 | 1 |
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19102821 | LOCK TO POLE BIOMETRIC ACCESS INTRAVENEOUS MEDICATION LOCKBOX | WIEST, PHILIP R | — | §103 | Non-Final OA | — | Pending | Feb 10, 2025 |
| 18830683 | COMPOSITION AND METHOD FOR GENERATING IMMUNITY TO BORRELIA BURGDORFERI | GRASER, JENNIFER E | — | DP | Non-Final OA | — | Pending | Sep 11, 2024 |
| 18708140 | DEPLETING EGFR AND HER2 OVERCOMES RESISTANCE TO EGFR INHIBITORS IN COLORECTAL CANCER | JONES-FOSTER, ERICA NICOLE | 1656 | §103 | Non-Final OA | — | Pending | May 07, 2024 |
| 18691035 | METHOD OF MITIGATION OF INJURIES CAUSED BY SYSTEMIC GENOTOXIC STRESS | PAGUIO FRISING, MICHELLE F | 1651 | §112 | Non-Final OA | — | Pending | Mar 11, 2024 |
| 18439315 | METHOD FOR PROPHYLAXIS AND/OR TREATMENT OF ErbB2 POSITIVE CANCERS | REDDIG, PETER J | 1642 | §101§102§103DP | Non-Final OA | — | Pending | Feb 12, 2024 |
| 18259763 | ANTI-SURVIVIN ANTIBODIES FOR TREATMENT OF AUTOIMMUNE DISEASES | PETERS, ALEC JON | 1641 | §102§103§112DP | Non-Final OA | — | Pending | Jun 28, 2023 |
| 18253384 | COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH | RZECZYCKI, PHILLIP MATTHEW | 1625 | §102§112 | Final Rejection | 60d overdue | Pending | May 17, 2023 |
| 18249816 | SYNERGISTIC INDUCTION OF IMMUNITY AGAINST RNA VIRUSES | HELLMAN, KRISTINA M | 1654 | §102§103§112 | Final Rejection | — | Pending | Apr 20, 2023 |
| 18162995 | METHOD AND SYSTEM FOR CONCURRENT PHOTOTHERMAL ABLATION AND INTERSTITIAL PHOTODYNAMIC THERAPY | MULLINS, JESSICA LYNN | 3792 | §102§103 | Non-Final OA | — | Pending | Feb 01, 2023 |
| 17638518 | REACTIVATING P53 MUTANTS FOR CANCER TREATMENT BY TARGETING PROLIDASE (PEPD) | HUDSON, AMY ROSE | 1636 | §103§112 | Non-Final OA | — | Pending | Feb 25, 2022 |
| 17523079 | ANTI-MICROBIAL PEPTIDES AND METHOD FOR DESIGNING NOVEL ANTI-MICROBIAL PEPTIDES | FONSECA LOPEZ, FRANCINI ALVARENGA | 1685 | §103 | Final Rejection | 34d | Pending | Nov 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial